Effect of ulinastatin on the expression and distribution of high mobility group box 1 in human colon carcinoma cells in vitro

Wang, Yunhua; Tao, Tao; Dong, Yinv; Zhang, Jing; Qin, Zaisheng

doi:10.3892/mmr.2014.2921

Cited by 7 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such effects of Ulinastatin inhibiting HMGB-1 expression and HMGB-1 mediated inflammatory responses has been reported by other authors [190,191]. Zhao et.al demonstrated that ulinastatin inhibited the hepatic hypoxia/reoxygenation (H/R) injury in Chang liver cells, and concluded that it might be due to autophagy activation [192].…”

Section: B Ulinastatin Downregulates Hmgb-1 Expression and Proinflammatory Cytokinessupporting

confidence: 63%

Combinations of drugs might increase the survival chances of COVID-19 patients: Literature review till date

Karthik¹

2021

Preprint

View full text Add to dashboard Cite

show abstract

Section: B Ulinastatin Downregulates Hmgb-1 Expression and Proinflammatory Cytokinessupporting

confidence: 63%

Combinations of drugs might increase the survival chances of COVID-19 patients: Literature review till date

Karthik¹

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Another study was conducted to investigate the in vitro effects of ulinastatin (UTI) on the proliferation, invasion, apoptosis, expression, and distribution of high mobility group box 1 (HMGB1) and the expression of nuclear factor κB (NF-κB) in human colon carcinoma LoVo cells. It was found that UTI inhibited the expression of HMGB1 and NF-κB, and decreased the cytoplasmic distribution of HMGB1 [ 26 ]. The prognostic effect of HMGB1 was also detected.…”

Section: Discussionmentioning

confidence: 99%

Association of HMGB1 Gene Polymorphisms with Risk of Colorectal Cancer in a Chinese Population

Wang

Bei

et al. 2016

Med Sci Monit

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. More advanced work is required in the detection of biomarkers for CRC susceptibility and prognosis. High-mobility group box-1 (HMGB1) is an angiogenesis-related gene reported to be associated with the development of CRC. The direct evidence of HMGB1 gene polymorphisms as biomarkers for CRC has not been reported previously.Material/MethodsA total of 240 CRC patients and 480 healthy controls were periodically enrolled. DNA was extracted from blood specimens. The distributions of SNPs of HMGB1 were determined by using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay.ResultsIn this case-control study, we observed a significant association between overall CRC risk and SNP rs2249825 (CG vs. CC and GG vs. CC). Participants carrying both rs2249825 CG (OR, 2.67; 95% CI, 1.89 to 3.78) and rs2249825 GG genotypes (OR, 2.32; 95% CI, 1.13 to 4.73) had a significantly increased risk of developing CRC compared to those carrying GG genotype. rs2249825 was associated with the risk of CRC in the dominant model but not in the recessive model. However, we found no significant differences in the rs1412125 or rs1045411 polymorphisms in the HMGB1. Advanced analyses showed that the number of rs2249825 G alleles showed a significant relationship with risk of CRC.ConclusionsOur results show an association between HMGB1 rs2249825 SNP and CRC incidence in the Chinese Han population. However, population-based studies with more subjects and prognostic effects are needed to verify the association of HMGB1 SNPs with CRC susceptibility, severity, and long-term prognosis.

show abstract

“…However, the underlying molecular mechanisms remain unclear. A recent study showed eight genes (EGF, CDK1, ENDRA, NGFR, OIP5, NUF2, and CDCA8) are predicted to be involved in carcinogenesis pathways (23). But, the study involved only TCGA dataset which did not represent a generalization.…”

Section: Discussionmentioning

confidence: 99%

Identification of CDC20 as a Novel Biomarker in Diagnosis and Treatment of Wilms Tumor

Shi

Tang

et al. 2021

Front. Pediatr.

View full text Add to dashboard Cite

Objective: Wilms tumor (WT) is a common malignant solid tumor in children. Many tumor biomarkers have been reported; however, there are poorly targetable molecular mechanisms which have been defined in WT. This study aimed to identify the oncogene in WT and explore the potential mechanisms.Methods: Differentially expressed genes (DEGs) in three independent RNA-seq datasets were downloaded from The Cancer Genome Atlas data portal and the Gene Expression Omnibus database (GSE66405 and GSE73209). The common DEGs were then subjected to Gene Ontology enrichment analysis, protein–protein interaction (PPI) network analysis, and gene set enrichment analysis. The protein expression levels of the hub gene were analyzed by immunohistochemical analysis and Western blotting in a 60 WT sample. The univariate Kaplan–Meier analysis for overall survival was performed, and the log-rank test was utilized. A small interfering RNA targeting cell division cycle 20 (CDC20) was transfected into G401 and SK-NEP-1 cell lines. The Cell Counting Kit-8 assay and wound healing assay were used to observe the changes in cell proliferation and migration after transfection. Flow cytometry was used to detect the effect on the cell cycle. Western blot was conducted to study the changes of related functional proteins.Results: We commonly identified 44 upregulation and 272 downregulation differentially expressed genes in three independent RNA-seq datasets. Gene and pathway enrichment analyses of the regulatory networks involving hub genes suggested that cell cycle changes are crucial in WT. The top 15 highly connected genes were found by PPI network analysis. Furthermore, we demonstrated that one candidate biomarker, CDC20, for the diagnosis of WT was detected, and its high expression predicted poor prognosis of WT patients. Moreover, the area under the curve value obtained by receiver operating characteristic curve analysis from paired WT samples was 0.9181. Finally, we found that the suppression of CDC20 inhibited proliferation and migration and resulted in G2/M phase arrest in WT cells. The mechanism may be involved in increasing the protein level of securin, cyclin B1, and cyclin AConclusion: Our results suggest that CDC20 could serve as a candidate diagnostic and prognostic biomarker for WT, and suppression of CDC20 may be a potential approach for the prevention and treatment of WT.

show abstract

Effect of ulinastatin on the expression and distribution of high mobility group box 1 in human colon carcinoma cells in vitro

Cited by 7 publications

References 55 publications

Combinations of drugs might increase the survival chances of COVID-19 patients: Literature review till date

Combinations of drugs might increase the survival chances of COVID-19 patients: Literature review till date

Association of HMGB1 Gene Polymorphisms with Risk of Colorectal Cancer in a Chinese Population

Identification of CDC20 as a Novel Biomarker in Diagnosis and Treatment of Wilms Tumor

Contact Info

Product

Resources

About